Financial Performance - The company's operating revenue for Q1 2022 was CNY 322,719,191.72, a decrease of 0.43% compared to CNY 324,097,123.51 in the same period last year[4] - Net profit attributable to shareholders increased by 8.79% to CNY 38,124,057.71 from CNY 35,043,698.73 year-on-year[4] - The net profit after deducting non-recurring gains and losses rose by 9.38% to CNY 35,417,281.48 compared to CNY 32,378,567.30 in the previous year[4] - Operating profit for the first quarter was CNY 41,577,682.14, a slight increase from CNY 40,093,005.83 in the previous year, reflecting a growth of 3.7%[19] - Total revenue from sales of goods and services reached CNY 264,507,609.83, compared to CNY 230,956,278.36 in the prior year, marking an increase of 14.6%[22] - The net profit for the first quarter of 2022 was CNY 38,124,057.71, representing an increase of 8.0% compared to CNY 35,043,698.73 in the same period last year[19] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,975,466,545.59, reflecting a growth of 3.46% from CNY 1,909,438,088.21 at the end of the previous year[4] - Total liabilities at the end of the quarter were CNY 825,158,626.37, compared to CNY 797,282,506.70 at the beginning of the year, indicating an increase of approximately 3.5%[16] - The company's total assets increased to CNY 1,975,466,545.59 from CNY 1,909,438,088.21, reflecting a growth of about 3.5%[16] Cash Flow - The company's cash flow from operating activities improved by 17.27%, with a net outflow of CNY 18,417,173.83 compared to CNY 22,262,319.72 in the same period last year[4] - The cash flow from operating activities showed a net outflow of CNY -18,417,173.83, an improvement from CNY -22,262,319.72 in the same quarter last year[23] - The total cash inflow from financing activities was CNY 107,075,340.00, compared to CNY 179,000,000.00 in the previous year, indicating a decrease of 40.1%[24] - Investment activities resulted in a net cash outflow of CNY -115,496,056.70, worsening from CNY -53,766,585.30 in the same quarter last year[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,623[10] - The company reported a basic and diluted earnings per share of CNY 0.21, up from CNY 0.19 in the same quarter last year[20] Operational Metrics - Total operating costs for Q1 2022 were CNY 283,735,560.59, down from CNY 285,260,907.53 in the previous period, indicating a decrease of about 0.5%[18] - The company's cash and cash equivalents at the end of the quarter were CNY 189,090,940.55, down from CNY 250,301,867.27 at the beginning of the year, reflecting a decrease of approximately 24.4%[14] - Accounts receivable increased to CNY 122,144,942.45 from CNY 114,536,538.93, marking an increase of about 6.3%[14] - Inventory levels rose to CNY 380,668,863.94, compared to CNY 335,527,464.40 at the start of the year, representing an increase of approximately 13.4%[14] Borrowings - Long-term borrowings increased by 42.83% to CNY 357,075,340.00, attributed to financing for ongoing projects[8] - The company experienced a 90.91% reduction in short-term borrowings, decreasing to CNY 3,000,000.00 from CNY 33,000,000.00[8] - Short-term borrowings decreased significantly from CNY 33,000,000.00 to CNY 3,000,000.00, a reduction of about 90.9%[15] Research and Development - Research and development expenses increased to CNY 21,615,040.10, up 14.8% from CNY 18,827,629.40 year-over-year[19] Strategic Focus - The company continues to focus on expanding its product offerings and market presence, although specific new products or technologies were not detailed in the report[13]

珠海润都制药股份有限公司 2021 年第三季度报告 2021 年第三季度报告 2021 Third quarter report | 证 券 代 码 ： 00 2 92 3 | | --- | | 证 券 简 称 ： 润 都 股 份 | | 公 告 编 号 ： 20 2 1 -07 1 | 1 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中 财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 珠海润都制药股份有限公司 2021 年第三季度报告 证券代码：002923 证券简称：润都股份 公告编号：2021-071 珠海润都制药股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | ...

Financial Performance - The company reported a revenue of 500 million RMB for the first half of 2021, representing a year-on-year increase of 20%[16] - The net profit attributable to shareholders was 100 million RMB, up 15% compared to the same period last year[16] - The company reported a revenue of CNY 574.53 million for the first half of 2021, a decrease of 12.31% compared to CNY 655.17 million in the same period last year[22] - Net profit attributable to shareholders was CNY 64.58 million, down 15.43% from CNY 76.36 million year-on-year[22] - The company's operating revenue for the reporting period was ¥574,528,206.81, a decrease of 12.31% compared to ¥655,167,963.35 in the previous year, primarily due to macro policies, the pandemic, and product price fluctuations[46] - The company reported a significant decrease in cash flow from operating activities, which was ¥14,835,526.91, down 84.32% from ¥94,598,098.95 in the previous year, due to increased production scale and reduced current liabilities[46] - The total comprehensive income for the first half of 2021 was CNY 69.02 million, compared to CNY 77.28 million in the same period of 2020[168] Research and Development - The company plans to invest 50 million RMB in R&D for new drug development in the next fiscal year[16] - The company is focusing on the development of a new drug that targets chronic diseases, with clinical trials expected to begin in Q4 2021[16] - The company has established a strategic partnership with a leading research institution to enhance its R&D capabilities[16] - The company's R&D investment decreased by 18.30% to ¥39,634,607.06 from ¥48,513,233.03, attributed to the stage of ongoing R&D projects and fluctuations in clinical research costs[46] - The company aims to improve its R&D efficiency and core technology capabilities by adopting diversified R&D management models and attracting high-level R&D talent[68] Market Expansion - User data indicates a 30% increase in the number of active patients using the company's products[16] - The company has expanded its market presence by entering three new provinces, increasing its distribution network by 25%[16] - Future guidance estimates a revenue growth of 25% for the next half of the year, driven by new product launches[16] - The company is exploring potential acquisition opportunities to further expand its product portfolio and market reach[16] Production and Operations - The company is focusing on enhancing safety production, quality optimization, and implementing a multi-channel marketing strategy to penetrate broader markets[32] - The company has accelerated the clinical research of its innovative drug, and multiple products have been submitted for drug registration in the US, EU, Japan, and South Korea[31] - The company is advancing the construction of its "Formulation Workshop Capacity Upgrade Project" and has spent approximately CNY 263 million on the project as of June 2021[33] - The company is focused on enhancing production efficiency through automation and improving production management to meet annual production targets[34] - The company aims to expand its production capacity for active pharmaceutical ingredients and formulations to seize market opportunities and improve profitability[34] Financial Position - The total assets of the company increased by 9.08% to CNY 1.65 billion compared to the end of the previous year[22] - The net assets attributable to shareholders rose by 0.92% to CNY 1.05 billion[22] - The company's long-term borrowings increased significantly to CNY 240,000,000.00, reflecting a rise of 14.39% in proportion to total assets due to project financing[52] - The company's total liabilities decreased from CNY 475,538,501.01 at the end of 2020 to CNY 603,381,088.31, representing an increase of approximately 26.8%[155] Environmental and Social Responsibility - The company has implemented effective environmental management measures, ensuring wastewater treatment meets the standards set by the Guangdong Province and the pharmaceutical industry[84] - The company has upgraded its hazardous waste storage facilities in compliance with national standards[85] - The company has actively participated in public welfare activities, donating 750,000 RMB for poverty alleviation and rural revitalization projects during the reporting period[99] - The company has established a comprehensive employee rights protection system, ensuring compliance with labor laws and enhancing employee welfare[97] Shareholder and Corporate Governance - The company has developed a shareholder dividend return plan for 2020-2022, emphasizing the protection of shareholder and creditor rights[93] - The company held three shareholder meetings during the reporting period, with participation rates of 63.25% on January 28, 2021, 63.06% on May 18, 2021, and 63.53% on June 25, 2021[73][75][77] - The company plans not to distribute cash dividends or issue bonus shares for the semi-annual period[75] - The company reported a rental expense of 0.877 million yuan for office space in Guangzhou and 0.9713 million yuan for office space in Wuhan during the reporting period[118] Compliance and Legal Matters - The semi-annual financial report was not audited[107] - There were no significant litigation or arbitration matters during the reporting period[108] - The company did not have any violations regarding external guarantees during the reporting period[106] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[105]

Financial Performance - The company's operating revenue for 2020 was CNY 1,252,630,836.95, a decrease of 7.89% compared to CNY 1,359,908,295.50 in 2019[18]. - The net profit attributable to shareholders in 2020 was CNY 135,862,411.12, an increase of 14.27% from CNY 118,896,727.79 in 2019[18]. - The net profit after deducting non-recurring gains and losses was CNY 113,745,137.62, up 27.38% from CNY 89,294,936.87 in 2019[18]. - The net cash flow from operating activities increased by 65.46% to CNY 250,346,177.78 in 2020, compared to CNY 151,299,880.47 in 2019[18]. - The total assets at the end of 2020 were CNY 1,513,772,150.91, reflecting a 14.10% increase from CNY 1,326,680,483.36 at the end of 2019[19]. - The basic earnings per share for 2020 was CNY 0.74, representing a 15.63% increase from CNY 0.64 in 2019[18]. - The weighted average return on equity was 13.81% in 2020, slightly up from 13.28% in 2019[18]. - The company reported a total of CNY 22,117,273.50 in non-recurring gains for 2020, down from CNY 29,601,790.92 in 2019[24]. Dividend Distribution - The company plans to distribute a cash dividend of 4.00 CNY per 10 shares, amounting to an estimated total cash dividend of 74.35 million CNY based on a total share capital of 185.87 million shares[5]. - The cash dividend for 2020 represents 54.72% of the net profit attributable to the parent company, which was 135,862,411.12 CNY[116]. - The actual distributable profit for the parent company in 2020 was CNY 464,642,581.93, with a proposed cash dividend of CNY 4.00 per 10 shares, amounting to an estimated total cash dividend of CNY 74,347,840[118]. - The cash dividend policy has been confirmed to comply with the company's articles of association and shareholder resolutions[114]. Risk Management - The board of directors confirmed that there are no significant risks affecting the company's operations during the reporting period[5]. - The company has outlined various risks and countermeasures in the annual report, which investors are encouraged to review[5]. - The company has faced risks related to fundraising investment projects due to potential policy and market changes, which could impact expected returns[108]. - The company has implemented measures to strengthen fundraising management and adjust investment projects in response to market conditions[108]. Research and Development - The company has established a research institute in Wuhan to enhance its research and development capabilities[9]. - The company invested ¥102.47 million in R&D during 2020, focusing on both independent and collaborative development projects[45]. - The company’s R&D efforts focus on innovative drug delivery systems, with 9 enteric-coated and sustained-release products already on the market[37]. - The company plans to strengthen its R&D capabilities by increasing investment and accelerating the development of innovative drugs[103]. Market Strategy - The company is focused on expanding its market presence and developing new products to meet consumer needs[10]. - The company aims to enhance its core competitiveness and expand both domestic and international markets, focusing on raw materials and preparations[99]. - The company will implement a macro marketing strategy for formulations, focusing on six core product areas and expanding marketing channels[102]. Production and Operations - The company is committed to adhering to Good Manufacturing Practice (GMP) standards in its production processes[10]. - The company has a well-defined procurement, production, and sales model, ensuring quality control and market responsiveness[29]. - The company has developed a complete industrial chain from raw materials to formulations, enhancing its market competitiveness[37]. - The company’s Zhuhai plant covers an area of 112,900 square meters, with fixed asset additions of about ¥160 million in 2020[50]. Environmental and Social Responsibility - The company has been recognized as a national green factory, adhering to environmental management standards and achieving compliance in pollutant emissions[150][158]. - The company actively participated in social responsibility initiatives, contributing 100,000 RMB to support education in poverty-stricken areas[154]. - The company has invested 66.92 million RMB in various poverty alleviation efforts, including educational support for underprivileged students[155]. Shareholder Information - The company has established a shareholder return plan for 2020-2022, emphasizing the protection of shareholder rights and interests[149]. - Major shareholders include Li Xi and Chen Xinmin, each holding 29.81% of the shares, totaling 55,420,875 shares[188]. - The company’s total number of restricted shares released for trading during the reporting period was 2,167,800 shares[178]. - The company has implemented a stock incentive plan for 106 individuals, which will increase liabilities until the options are exercised[186]. Compliance and Governance - The company did not experience any significant accounting errors requiring restatement during the reporting period[126]. - There were no changes in the scope of the consolidated financial statements compared to the previous year[127]. - The company did not engage in any major litigation or arbitration during the reporting period[129]. - The company has no major guarantees or entrusted loans during the reporting period[144][147].

Revenue and Profit - The company's revenue for Q1 2021 was ¥324,097,123.51, representing a 2.00% increase compared to ¥317,755,476.17 in the same period last year[7] - Net profit attributable to shareholders was ¥35,043,698.73, up 9.61% from ¥31,971,613.75 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥32,378,567.30, reflecting a 15.51% increase from ¥28,031,016.40 in the previous year[7] - Basic earnings per share for the period were ¥0.19, a 5.56% increase from ¥0.18 in the same period last year[7] - The company reported a total comprehensive income of CNY 35,043,698.73 for Q1 2021, compared to CNY 31,971,613.75 in the previous period[45] - The net profit for the first quarter of 2021 was CNY 38,288,688.09, an increase from CNY 37,716,011.97 in the same period last year, representing a growth of approximately 1.52%[48] - The total profit for the quarter reached CNY 44,661,321.46, up from CNY 41,326,202.35, reflecting a growth of approximately 8.00%[48] Cash Flow - The net cash flow from operating activities was -¥22,262,319.72, a significant decrease of 139.48% compared to ¥56,392,334.38 in the same period last year[7] - Cash flow from operating activities showed a net outflow of CNY -22,262,319.72, a significant decrease compared to a net inflow of CNY 56,392,334.38 in the previous year[52] - The company reported cash inflow from operating activities of CNY 239,807,630.11, down from CNY 275,882,551.27 in the previous year, indicating a decline of approximately 13.06%[52] - The company's operating cash outflow totaled CNY 262,069,949.83, compared to CNY 219,490,216.89 in the previous year, indicating an increase of approximately 19.30%[52] - The company reported a net cash outflow from financing activities of -2,512,121.27 CNY in Q1 2021, compared to a net inflow of 53,029,058.49 CNY in Q1 2020[56] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,625,348,353.61, an increase of 7.37% from ¥1,513,772,150.91 at the end of the previous year[7] - The net assets attributable to shareholders were ¥1,075,360,811.10, up 3.58% from ¥1,038,233,649.90 at the end of the previous year[7] - Total liabilities decreased to CNY 549,987,542.51 from CNY 475,538,501.01, a reduction of about 15.59%[36] - The company's equity increased to CNY 1,075,360,811.10 from CNY 1,038,233,649.90, showing a growth of approximately 3.58%[37] - Total liabilities decreased to CNY 307,749,914.22 from CNY 332,328,549.23[43] Investments and Expenses - The company received government subsidies amounting to ¥3,059,777.30 during the reporting period[8] - Research and development expenses for Q1 2021 were CNY 18,827,629.40, down from CNY 24,089,902.58 in the previous period, indicating a reduction of approximately 21.7%[43] - Sales expenses decreased to CNY 118,782,245.60 from CNY 121,338,018.14, a decline of about 2.1%[43] - The company reported an 84.04% decrease in investment income to ¥165,011.74, mainly due to reduced wealth management returns[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,846[11] - The total amount of funds raised from the public offering was ¥425,250,000.00, with a net amount of ¥345,610,300.00 after deducting issuance costs[24] Other Financial Metrics - The weighted average return on equity remained stable at 3.33%[7] - The company has a remaining balance of raised funds of ¥60,921,110.25, including interest income and wealth management returns[24] - The solid preparation workshop renovation project has achieved an investment progress of 72.89% as of March 31, 2021[24]

Financial Performance - Net profit attributable to shareholders increased by 3.66% to ¥34,481,781.88 for the current period[7] - Operating income decreased by 7.66% to ¥303,163,230.88 compared to the same period last year[7] - Basic earnings per share rose by 5.56% to ¥0.19[7] - The total profit for the period was CNY 37,976,738.88, down from CNY 40,301,426.03, reflecting a decline of about 5.4%[44] - Net profit for Q3 2020 was CNY 34,481,781.88, slightly up from CNY 33,264,994.49 in the same period last year, representing a growth of approximately 3.67%[44] - Net profit for the current period was ¥110,846,716.74, an increase of 12.50% compared to ¥98,583,567.81 in the previous period[52] - The total comprehensive income for the current period was ¥110,846,716.74, up from ¥98,583,567.81, marking an increase of 12.50%[53] - The total profit for the current period was ¥123,525,587.96, compared to ¥113,951,829.02 in the previous period, indicating an increase of 8.00%[52] Assets and Liabilities - Total assets increased by 10.38% to ¥1,464,323,937.54 compared to the end of the previous year[7] - Current liabilities increased to CNY 359,504,644.49, up 22.3% from CNY 293,871,711.00[36] - Non-current liabilities totaled CNY 96,268,083.99, a slight increase from CNY 92,514,061.59[36] - The company's equity attributable to shareholders rose to CNY 1,008,551,209.06, up from CNY 940,294,710.77, reflecting a growth of 7.3%[37] - Total liabilities rose to CNY 354,925,361.37 from CNY 275,108,512.08, reflecting an increase of approximately 28.9%[43] - Total assets reached CNY 1,326,680,483.36, with current assets accounting for CNY 781,099,060.82[66] - Total liabilities amounted to CNY 386,385,772.59, with current liabilities at CNY 293,871,711.00[67] - Owner's equity totaled CNY 940,294,710.77, reflecting a strong capital position[68] Cash Flow - Net cash flow from operating activities increased by 13.64% to ¥85,733,001.44[7] - The net cash flow from operating activities increased by 14.59% to ¥180,331,100.39[21] - The net cash flow from operating activities for Q3 2020 was CNY 180,331,100.39, an increase of 14.5% compared to CNY 157,368,913.39 in Q3 2019[59] - Total cash inflow from operating activities was CNY 925,049,663.34, while cash outflow was CNY 744,718,562.95, resulting in a net cash inflow of CNY 180,331,100.39[59] - Cash flow from investment activities showed a net outflow of CNY 99,716,804.69, compared to a smaller outflow of CNY 48,887,818.04 in the previous year[60] - Cash flow from financing activities resulted in a net outflow of CNY 23,187,387.92, an improvement from a net outflow of CNY 43,587,552.01 in Q3 2019[63] Shareholder Information - The total number of shareholders at the end of the reporting period was 12,262[11] - The top two shareholders, Li Xi and Chen Xinmin, each hold 29.81% of the shares, totaling 59.62% combined[12] Expenses - Operating costs increased by 22.85% to ¥343,219,658.63, primarily due to rising material costs[19] - Sales expenses decreased by 27.86% to ¥355,007,060.98, attributed to reduced academic and brand promotion activities[19] - Research and development expenses were ¥71,292,858.21, down 11.67% from the previous period[19] - Research and development expenses remained stable at CNY 22,779,625.18 compared to CNY 22,974,860.89, indicating consistent investment in innovation[43] - The company reported a decrease in sales expenses to CNY 103,408,856.66 from CNY 153,941,926.89, a reduction of approximately 32.8%[43] Financial Position - Fixed assets increased significantly to CNY 481,865,367.60 from CNY 325,457,941.68, representing a growth of 47.9%[35] - Deferred tax assets increased by 45.61% to ¥13,603,601.33, mainly due to increased expenses from stock incentives[19] - The company reported a financial expense of ¥2,592,781.82, compared to a financial income of -¥226,891.69 in the previous period[52] Other Information - The company reported a government subsidy income of ¥12,678,160.22 during the period[8] - Non-recurring gains and losses totaled ¥12,276,041.72 for the year-to-date[8] - The company implemented new accounting standards for revenue recognition, enhancing financial transparency[68] - The company implemented the new revenue recognition standard starting in 2020, adjusting the presentation of contract liabilities[74] - The Q3 report was not audited[74]

Financial Performance - The company reported a revenue of 1.5 billion RMB for the first half of 2020, representing a year-on-year increase of 15%[1] - The net profit attributable to shareholders was 300 million RMB, up 20% compared to the same period last year[1] - The company's operating revenue for the first half of 2020 was CNY 655,167,963.35, a decrease of 5.15% compared to CNY 690,754,883.28 in the same period last year[18] - Net profit attributable to shareholders increased by 16.91% to CNY 76,364,934.86, up from CNY 65,318,573.32 year-on-year[18] - The net profit after deducting non-recurring gains and losses rose by 26.44% to CNY 68,312,437.55, compared to CNY 54,029,614.12 in the previous year[18] - Basic earnings per share increased by 20.00% to CNY 0.42, compared to CNY 0.35 in the previous year[18] - The company achieved operating revenue of CNY 655.17 million, a year-on-year decrease of 5.15%[40] - Operating profit reached CNY 85.89 million, an increase of 16.01% year-on-year[40] - The company reported a total comprehensive income of ¥76,364,934.86 for the period[184] - The total comprehensive income for the period amounted to CNY 63,688,749.41, reflecting the company's performance during the first half of the year[198] Investment and R&D - The company plans to invest 200 million RMB in R&D for new drug development in the next fiscal year[1] - The company is actively pursuing partnerships with international CROs to accelerate drug development timelines[1] - The company holds 57 patents, including 32 invention patents, and submitted 17 patent applications in the first half of 2020[41] - The company is actively developing multiple raw material and formulation projects, with significant breakthroughs in domestic and international drug registration[41] - The company has committed to various investment projects, including a production base project with a total investment of ¥18,071 million, which has reached 100% completion[66] Market Expansion - The company has expanded its market presence in Southeast Asia, achieving a 30% growth in sales in that region[1] - New product launches are expected to contribute an additional 500 million RMB in revenue by the end of 2021[1] - The sales revenue of raw materials increased by 21.61% year-on-year, accounting for 43.08% of total operating revenue[40] - The revenue from raw materials increased by 30.22% to ¥258,147,523.77, while the cost of raw materials rose by 55.08%[53] - The revenue from the Central China region grew by 45.26%, with costs increasing by 114.66%, attributed to the expanded sales scale of raw materials[53] Financial Position - Total assets at the end of the reporting period were CNY 1,401,342,733.04, an increase of 5.63% from CNY 1,326,680,483.36 at the end of the previous year[18] - Net assets attributable to shareholders rose by 3.07% to CNY 969,158,331.79, compared to CNY 940,294,710.77 at the end of the previous year[18] - Cash and cash equivalents increased by 63.48%, totaling an increase of 125.58 million yuan, mainly due to the maturity of financial products[31] - The company's total liabilities increased to ¥432,184,401.25 as of June 30, 2020, compared to ¥386,385,772.59 at the end of 2019, an increase of about 11.85%[162] - The company's total equity reported a net increase to ¥974,136,234.09, showing a significant increase compared to the previous period[198] Corporate Governance and Compliance - The company has established a GMP management system for production, ensuring compliance with quality standards throughout the manufacturing process[28] - The company is committed to strict quality control measures in compliance with new regulations and standards in the pharmaceutical industry[81] - The company has implemented effective environmental protection measures, ensuring that wastewater and emissions meet the required standards[111][112][113] - The company has established an emergency response plan for environmental incidents, ensuring timely and effective actions to control pollution and protect the environment[116] - The company has a commitment to maintain shareholding restrictions for a period of 36 months following the listing of its shares[87] Shareholder Matters - The company will not distribute cash dividends or issue bonus shares for the half-year period[86] - The company granted 519,000 restricted stocks to 106 eligible participants at a price of 8.98 CNY per share on March 12, 2020[95] - The first unlock period for 2,167,800 shares from the 2019 restricted stock incentive plan was completed, allowing these shares to be traded starting May 13, 2020[96] - The company has a lock-up period for restricted shares, which varies from 12 to 36 months depending on the conditions met[137] - Major shareholders Li Xi and Chen Xinmin each hold 29.81% of the company, totaling 55,420,875 shares, which represents 59.62% of the total share capital[141] Risks and Challenges - The company is facing risks related to market competition due to significant changes in pharmaceutical industry policies and is responding by enhancing its core competitive advantages[80] - The company is aware of the risks associated with fundraising investment projects and is implementing adjustments to ensure expected returns[82] - The company predicts a significant change in cumulative net profit from the beginning of the year to the next reporting period, indicating potential losses or substantial fluctuations compared to the same period last year[80] Social Responsibility - The company invested CNY 100,000 in the "Ten Thousand Enterprises Help Ten Thousand Villages" poverty alleviation initiative, specifically for educational support in Puladi Village, Yunnan Province[120] - The total funding for poverty alleviation efforts during the reporting period amounted to CNY 100,000, all directed towards educational assistance for outstanding students in the village[121] - The company plans to continue its annual investment of CNY 100,000 in educational support for Puladi Village from 2018 to 2020[122]

珠海润都制药股份有限公司 2020 年第一季度报告全文 2020 年第一季度报告 2020 First quarter report 证 券 代 码 ： 00 2 92 3 证 券 简 称 ： 润 都 股 份 公 告 编 号 ： 20 2 0 -03 5 珠海润都制药股份有限公司 2020 年 04 月 1 珠海润都制药股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人刘杰、主管会计工作负责人刘杰及会计机构负责人(会计主管人 员)石深华声明：保证季度报告中财务报表的真实、准确、完整。 2 珠海润都制药股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 其他原因 | | 本报告期 | 上年同期 | | 本报告期比上年同 | | --- | --- | --- | --- | ...

Financial Performance - The company's operating revenue for 2019 was CNY 1,359,908,295.50, representing a 30.28% increase compared to CNY 1,043,860,465.03 in 2018[18]. - The net profit attributable to shareholders for 2019 was CNY 118,896,727.79, an increase of 11.28% from CNY 106,844,362.93 in 2018[18]. - The net profit after deducting non-recurring gains and losses was CNY 89,294,936.87, reflecting a 5.49% increase from CNY 84,649,225.50 in 2018[18]. - The company's total assets at the end of 2019 were CNY 1,326,680,483.36, a 16.54% increase from CNY 1,138,419,861.16 at the end of 2018[19]. - The net assets attributable to shareholders at the end of 2019 were CNY 940,294,710.77, up 7.92% from CNY 871,294,552.20 at the end of 2018[19]. - The basic earnings per share for 2019 was CNY 0.64, compared to CNY 0.91 in 2018, marking an 8.47% increase from CNY 0.59 in 2017[19]. - The weighted average return on equity for 2019 was 13.28%, slightly up from 12.97% in 2018[19]. - The net cash flow from operating activities for 2019 was CNY 151,299,880.47, a decrease of 4.87% from CNY 159,043,847.38 in 2018[18]. Dividend Distribution - The company plans to distribute a cash dividend of 4.00 CNY per 10 shares, amounting to an estimated total cash dividend of 74.17 million CNY based on a total share capital of 185.42 million shares[4]. - The cash dividend for 2018 was also 74,167,800 CNY, distributed at 6.00 CNY per 10 shares (including tax), with a capital reserve conversion of 5 shares for every 10 shares held[126]. - The cash dividends for 2019, 2018, and 2017 represented 62.38%, 69.42%, and 77.22% of the net profit attributable to the company's ordinary shareholders, respectively[126]. - The company's total distributable profit for 2019 was 409,499,035.42 CNY, after accounting for the cash dividend distribution[128]. - The company has committed to maintaining a minimum cash dividend ratio of 20% during profit distributions, given its growth stage and significant capital expenditure plans[127]. Research and Development - R&D investment increased by 73.49% to CNY 114.54 million, supporting the development of new products and technologies[44]. - The company is committed to increasing its investment in research and development to leverage its 20 years of experience in drug development and production technology[104]. - The company will continue to increase R&D investment, focusing on the development of generic oral solid formulations and new raw materials, aiming to enhance its product line and market competitiveness[108]. - The number of R&D personnel increased by 10.26% to 215, while the proportion of R&D personnel to total staff decreased slightly to 15.96%[73]. Market and Product Strategy - The main business remains unchanged, focusing on the R&D, production, and sales of chemical raw materials and pharmaceutical intermediates, with key products including Rabeprazole Sodium and Irbesartan capsules[28]. - The company aims to strengthen its market position by expanding its product offerings and enhancing its R&D capabilities[31]. - The company is implementing a marketing strategy focused on "restructuring the pattern and sinking marketing" to enhance its sales management in 2020[107]. - The company plans to enhance its core competitiveness by focusing on the development of cardiovascular, digestive, and diabetes treatment products, while also advancing innovative drug research[104]. Risk Management - The company has outlined potential risks in its operations and has detailed measures to mitigate these risks in the annual report[4]. - The company is actively addressing market competition risks by adjusting its development strategy to enhance the competitiveness of its raw materials and formulations[114]. Environmental and Social Responsibility - The company has implemented an environmental management system that meets ISO 14001 standards and successfully passed the annual supervision audit[161]. - The company achieved a significant reduction in hazardous waste generation, decreasing the annual production of waste sludge by two-thirds through the introduction of a drying process[162]. - The company invested CNY 100,000 in educational poverty alleviation projects in Puladi Village, Yunnan Province, as part of the "Ten Thousand Enterprises Help Ten Thousand Villages" initiative[165]. - The company is committed to investing CNY 100,000 annually from 2018 to 2020 for educational support in Puladi Village, ensuring ongoing assistance[168]. Corporate Governance - The board of directors confirmed that all members attended the meeting to review the annual report, ensuring the accuracy and completeness of the financial statements[3]. - The company has ensured that minority shareholders have had sufficient opportunities to express their opinions and that their legal rights are protected[122]. - The company has revised its articles of association and governance rules to enhance shareholder rights and ensure transparency in major decisions[160]. Shareholder Information - The company’s total number of shareholders at the end of the reporting period was 17,647[198]. - The major shareholders, Li Xi and Chen Xinmin, each hold 29.89% of the company, collectively controlling 59.78% of the total shares[199]. - The company has a total of 55,420,875 shares held by Li Xi and Chen Xinmin, indicating significant ownership concentration[199]. - The company’s stock was listed on May 13, 2019, following the issuance of the restricted shares[194].

Financial Performance - Operating revenue for the third quarter was ¥328,323,979.15, representing a year-on-year growth of 20.03%[7] - Net profit attributable to shareholders was ¥33,264,994.49, reflecting a 15.99% increase compared to the same period last year[7] - Basic earnings per share for the quarter were ¥0.18, a 12.50% increase from the previous year[7] - The company reported a net profit attributable to shareholders after deducting non-recurring gains and losses of ¥27,289,228.94, up 16.77% year-on-year[7] - Revenue for the first nine months of 2019 reached ¥1,019,078,862.43, a 35.78% increase driven by higher sales volume of main products[18] - Net profit for Q3 2019 was ¥33,264,994.49, representing a growth of 15.5% from ¥28,677,980.08 in Q3 2018[43] - The company achieved a comprehensive income total of ¥98,583,567.81, up from ¥80,858,048.42 in the previous period[51] - Total operating revenue for the period reached ¥1,019,078,862.43, an increase of 35.8% compared to ¥750,537,478.41 in the previous period[48] - Net profit for the period was ¥98,583,567.81, representing a growth of 22% from ¥80,858,048.42 in the same period last year[50] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,314,915,910.22, an increase of 15.50% compared to the previous year-end[7] - The company's cash and cash equivalents increased by 36.64% to ¥249,364,384.59 due to increased cash inflows[16] - Accounts receivable rose by 82.42% to ¥128,100,719.15, attributed to expanded sales scale and changes in customer structure[16] - The total inventory rose by 31.57% to ¥225,132,696.93, driven by increased production and sales scale[16] - Total liabilities increased to CNY 403.02 million from CNY 267.13 million, a rise of 50.8%[33] - The company reported a significant increase in other payables, which surged to CNY 229.81 million from CNY 69.31 million, a growth of 231.5%[33] - Long-term borrowings decreased by 45.96% to ¥15,835,686.06 due to repayment of maturing bank loans[16] - Total current assets amounted to CNY 774,755,173.40, with cash and cash equivalents at CNY 182,500,917.42 and accounts receivable at CNY 70,222,458.04[66] Cash Flow - The net cash flow from operating activities was ¥75,444,535.53, up 52.37% year-on-year[7] - Net cash flow from operating activities improved by 87.57% to ¥157,368,913.39, resulting from expanded sales and increased cash collection[20] - Cash inflows from operating activities amounted to CNY 984.82 million, up from CNY 740.04 million, representing a growth of 33.0%[58] - The total cash inflow from operating activities was CNY 984.82 million, while total cash outflow was CNY 827.45 million, resulting in a net cash flow of CNY 157.37 million[58] - The net cash flow from investing activities was negative CNY 48.89 million, an improvement from negative CNY 416.26 million in the previous period[59] Research and Development - R&D investment surged by 92.87% to ¥80,711,012.67, reflecting ongoing increases in research and development efforts[18] - Research and development expenses increased to ¥22,974,860.89, up from ¥19,365,410.88, reflecting a focus on innovation[41] - Research and development expenses increased to ¥80,711,012.67, up 92.8% from ¥41,847,883.55 in the previous period, indicating a strong focus on innovation[48] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,327[11] - The top two shareholders, Li Xi and Chen Xinmin, each hold 29.89% of the shares, totaling 55,420,875 shares[11] Government Support - The company received government subsidies amounting to ¥14,219,959.77 during the reporting period[9] Corporate Governance - The company has committed to not transferring or entrusting its shares for twelve months following its stock listing[23] - The company has implemented measures to stabilize its stock price, including share buybacks and increasing shareholdings by actual controllers[23] - The company has committed to avoiding competition with its subsidiaries during the tenure of its directors and senior management[23] - The company has ensured that all commitments made by its directors and senior management are being fulfilled on time[23] Market Strategy - The company is focusing on market expansion and new product development as part of its growth strategy[48]